Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease

Genes and Cancer

Volumn 6, Issue 9-10, 2015, Pages 378-398

  Fleury, Hubert ^a,b   Communal, Laudine ^a,b   Carmona, Euridice ^a,b   Portelance, Lise ^a,b   Arcand, Suzanna L ^c   Rahimi, Kurosh ^a   Tonin, Patricia N ^c,d   Provencher, Diane ^a,b,e   Mes Masson, Anne Marie ^a,b,e  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Institut du Cancer de Montreal   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

BRCA mutations; Cell lines; Epithelial ovarian cancer; High grade serous

Indexed keywords

B RAF KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; COMPLEMENTARY DNA; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; TRANSCRIPTION FACTOR PAX8;

ANIMAL EXPERIMENT; ARTICLE; BRCA2 GENE; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; GENOMIC INSTABILITY; GERMLINE MUTATION; HUMAN; HUMAN TISSUE; IC50; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; SPHEROID CELL; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; WOUND HEALING;

EID: 84945940425     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29.
2. Gurung A, Hung T, Morin J and Gilks CB. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology. 2013; 62(1):59-70.
3. Le Page C, Provencher D, Maugard CM, Ouellet V and Mes-Masson AM. Signature of a silent killer: expression profiling in epithelial ovarian cancer. Expert Rev Mol Diagn. 2004; 4(2):157-167.
4. Bookman MA. First-line chemotherapy in epithelial ovarian cancer. Clin Obstet Gynecol. 2012; 55(1):96-113.
5. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T and Trimble E. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011; 21(4):750-755.
6. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011; 377(9760):127-138.
7. Cho KR and Shih Ie M. Ovarian cancer. Annu Rev Pathol. 2009; 4:287-313.
8. Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012; 23 Suppl 10:x111-117.
9. Wei W, Dizon D, Vathipadiekal V and Birrer MJ. Ovarian cancer: genomic analysis. Ann Oncol. 2013; 24 Suppl 10:x7-15.
10. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, Wang Y, Kurman RJ, Shih Ie M and Wang TL. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009; 69(9):4036-4042.
11. Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, Puiffe ML, Arcand SL, Shen Z, Hebert J, Tonin PN, Provencher DM and Mes-Masson AM. Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer. 2008; 8:152.
12. Network TCGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-615.
13. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D and Brenton JD. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010; 221(1):49-56.
14. McAlpine JN, Porter H, Kobel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG and Gilks CB. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012; 25(5):740-750.
15. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008; 8:17.
16. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 2013; 231(1):21-34.
17. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, Okamoto A, Urashima M, Smyth GK, Campbell IG and Bowtell DD. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS One. 2010; 5(9).
18. Wojnarowicz PM, Oros KK, Quinn MC, Arcand SL, Gambaro K, Madore J, Birch AH, de Ladurantaye M, Rahimi K, Provencher DM, Mes-Masson AM, Greenwood CM and Tonin PN. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS One. 2012; 7(9):e45484.
19. Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA and Wisman GB. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Gynecol Oncol. 2014; 133(3):591-598.
20. Keita M, Bachvarova M, Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Trinh XB and Bachvarov D. The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle. 2013; 12(6):972-986.
21. Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei Y, Li Y, Yang Q, Liu J, Wei JJ, Shao C, Liu Z and Kong B. MiR- 145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget. 2014; 5(21):10816-10829.
22. Chapman-Rothe N, Curry E, Zeller C, Liber D, Stronach E, Gabra H, Ghaem-Maghami S and Brown R. Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells. Oncogene. 2013; 32(38):4586-4592.
23. Domcke S, Sinha R, Levine DA, Sander C and Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013; 4:2126.
24. Jacob F, Nixdorf S, Hacker NF and Heinzelmann-Schwarz VA. Reliable in vitro studies require appropriate ovarian cancer cell lines. J Ovarian Res. 2014; 7:60.
25. DelloRusso C, Welcsh PL, Wang W, Garcia RL, King MC and Swisher EM. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res. 2007; 5(1):35-45.
26. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, Wurz K, Higgins J, Villegas E and Taniguchi T. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009; 69(16):6381-6386.
27. Letourneau IJ, Quinn MC, Wang LL, Portelance L, Caceres KY, Cyr L, Delvoye N, Meunier L, de Ladurantaye M, Shen Z, Arcand SL, Tonin PN, Provencher DM and Mes-Masson AM. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer. 2012; 12:379.
28. Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P and Narod SA. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 1998; 63(5):1341-1351.
29. Oros KK, Ghadirian P, Greenwood CM, Perret C, Shen Z, Paredes Y, Arcand SL, Mes-Masson AM, Narod SA, Foulkes WD, Provencher D and Tonin PN. Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer. 2004; 112(3):411-419.
30. Roy R, Chun J and Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2012; 12(1):68-78.
31. Huen MS, Sy SM and Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol. 2010; 11(2):138-148.
32. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013; 24 Suppl 10:x16-21.
33. Payne DJ, Gwynn MN, Holmes DJ and Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007; 6(1):29-40.
34. Singer G, Oldt R, 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ and Shih Ie M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003; 95(6):484-486.
35. Wojnarowicz PM, Provencher DM, Mes-Masson AM and Tonin PN. Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. Int J Oncol. 2012; 40(6):1865-1880.
36. Kobel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GL, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich K, Edwards R, et al. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev. 2013; 22(10):1677-1686.
37. Kommoss S, Gilks CB, Kommoss F, Chow C, Hilpert F, du Bois A, Kobel M, Huntsman DG, Anglesio M, Kalloger SE and Pfisterer J. Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. Histopathology. 2013; 63(5):704-712.
38. Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R and Hirsch MS. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011; 35(6):816-826.
39. Madore J, Ren F, Filali-Mouhim A, Sanchez L, Kobel M, Tonin PN, Huntsman D, Provencher DM and Mes-Masson AM. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol. 2010; 220(3):392-400.
40. Meden H and Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol. 1997; 71(2):173-179.
41. Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M and De la Garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev. 2006; 32(3):180-190.
42. Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, Wang JC, Eydoux P, Savoie R, Tonin PN and Mes-Masson AM. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim. 2000; 36(6):357-361.
43. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1992; 1(1):45-49.
44. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol. 1998; 8(5):345-357.
45. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R and Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003; 100(14):8424-8429.
46. Lee MK, Teoh WW, Phang BH, Tong WM, Wang ZQ and Sabapathy K. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer Cell. 2012; 22(6):751-764.
47. Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM and Mes-Masson AM. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog. 2007; 46(10):872-885.
48. Meunier L, Puiffe ML, Le Page C, Filali-Mouhim A, Chevrette M, Tonin PN, Provencher DM and Mes-Masson AM. Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model. Transl Oncol. 2010; 3(4):230-238.
49. Fujita M, Enomoto T and Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol. 2003; 202(1-2):97-99.
50. Kobel M, Huntsman D and Gilks CB. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med. 2008; 10:e22.
51. Do K and Chen AP. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res. 2013; 19(5):977-984.
52. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J and Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triplenegative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011; 12(9):852-861.
53. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J and Matulonis U. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Engl J Med. 2012; 366(15):1382-1392.
54. Liu JF, Konstantinopoulos PA and Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014; 133(2):362-369.
55. Olaparib Approved for Advanced Ovarian Cancer. Cancer Discov. 2015.
56. Cavallone L, Arcand SL, Maugard CM, Nolet S, Gaboury LA, Mes-Masson AM, Ghadirian P, Provencher D and Tonin PN. Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. Fam Cancer. 2010; 9(4):507-517.
57. Tonin PN, Maugard CM, Perret C, Mes-Masson AM and Provencher DM. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Fam Cancer. 2007; 6(4):491-497.
58. Kreuzinger C, Gamperl M, Wolf A, Heinze G, Geroldinger A, Lambrechts D, Boeckx B, Smeets D, Horvat R, Aust S, Hamilton G, Zeillinger R and Cacsire Castillo-Tong D. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. Cancer Lett. 2015; 362(2):218-228.
59. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RC and Smyth JF. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res. 1988; 48(21):6166-6172.
60. Kalluri R and Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest. 2009; 119(6):1420-1428.
61. Stewart CJ and McCluggage WG. Epithelial-mesenchymal transition in carcinomas of the female genital tract. Histopathology. 2013; 62(1):31-43.
62. Auer K, Bachmayr-Heyda A, Aust S, Sukhbaatar N, Reiner AT, Grimm C, Horvat R, Zeillinger R and Pils D. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. Oncotarget. 2015.
63. Vousden KH and Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137(3):413-431.
64. Brady CA and Attardi LD. P53 at a glance. J Cell Sci. 2010; 123(Pt 15):2527-2532.
65. Aylon Y and Oren M. New plays in the p53 theater. Curr Opin Genet Dev. 2011; 21(1):86-92.
66. Vousden KH and Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002; 2(8):594-604.
67. Vousden KH and Ryan KM. P53 and metabolism. Nat Rev Cancer. 2009; 9(10):691-700.
68. Mahmoudi S, Henriksson S, Corcoran M, Mendez-Vidal C, Wiman KG and Farnebo M. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell. 2009; 33(4):462-471.
69. Vilborg A, Wilhelm MT and Wiman KG. Regulation of tumor suppressor p53 at the RNA level. J Mol Med (Berl). 2010; 88(7):645-652.
70. Saldana-Meyer R and Recillas-Targa F. Transcriptional and epigenetic regulation of the p53 tumor suppressor gene. Epigenetics. 2011; 6(9):1068-1077.
71. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih Ie M and Kurman RJ. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011; 24(9):1248-1253.
72. Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, Greenwood CM, Mes-Masson AM and Tonin PN. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One. 2011; 6(12):e28250.
73. Sereni MI, Baldelli E, Gambara G, Zanotti L, Bandiera E, Bignotti E, Ragnoli M, Tognon G, Ravaggi A, Meani F, Memo M, Angioli R, Liotta LA, Pecorelli SL, Petricoin E, 3rd and Pierobon M. Functional characterization of epithelial ovarian cancer histotypes by drug target-based protein signaling activation mapping: implications for personalized cancer therapy. Proteomics. 2014.
74. Zannoni GF, Morassi F, Prisco MG, De Stefano I, Vellone VG, Arena V, Scambia G and Gallo D. Clinicopathologic and immunohistochemical features of ovarian clear cell carcinomas in comparison with type I and type II tumors. Int J Gynecol Pathol. 2012; 31(6):507-516.
75. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S161-192.
76. Lounis H, Provencher D, Godbout C, Fink D, Milot MJ and Mes-Masson AM. Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res. 1994; 215(2):303-309.
77. Belanger MH, Dolman L, Arcand SL, Shen Z, Chong G, Mes-Masson AM, Provencher D and Tonin PN. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population. J Ovarian Res. 2015; 8(1):1.
78. Oros KK, Arcand SL, Bayani J, Squire JA, Mes-Masson AM, Tonin PN and Greenwood CM. Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance. Cancer Genet. 2013; 206(4):103-115.
79. Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM and Mes-Masson AM. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia. 2007; 9(10):820-829.
80. Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006; 1(5):2315-2319.